Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

被引:161
作者
Haibel, H
Rudwaleit, M
Listing, J
Sieper, J
机构
[1] Dept Med 1, Charite, D-12200 Berlin, Germany
[2] German Rheumatism Res Ctr, Berlin, Germany
关键词
D O I
10.1136/ard.2004.023176
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine the therapeutic effect of the interleukin 1 (IL1) receptor antagonist anakinra in ankylosing spondylitis in an open label trial. Methods: Anakinra (100 mg) was given subcutaneously daily over 24 weeks to 20 NSAID refractory patients with ankylosing spondylitis. Thirteen completed the study. Clinical outcome assessments included disease activity, function, metrology, patients' and physicians' global assessment, peripheral joint assessment, quality of life, and C reactive protein. Dynamic magnetic resonance imaging (MRI) of sacroiliac joints or spine, using gadolinium DTPA as contrast agent, was done before treatment in 15/20 patients, and in 10 patients at study end. The primary end point was the Bath ankylosing spondylitis disease activity index (BASDAI) and ASAS (assessments in ankylosing spondylitis) short term response after six months. Results: Using an intention to treat analysis, an ASAS 20% response (ASAS 20) was achieved in five patients, ASAS 40 in four, and ASAS 70 in two after 24 weeks. There was no change in mean C reactive protein (22.3 v 33.1 mg/l) or in MRI score. The drug was well tolerated. Injection site reaction was the commonest adverse event. Conclusions: In this open study, anakinra improved spinal symptoms in only a small subgroup of patients with active ankylosing spondylitis.
引用
收藏
页码:296 / 298
页数:3
相关论文
共 16 条
[1]  
Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO
[2]  
2-F
[3]   Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].
Brandt, J ;
Khariouzov, A ;
Listing, J ;
Haibel, H ;
Sörensen, H ;
Grassnickel, L ;
Rudwaleit, M ;
Sieper, J ;
Braun, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675
[4]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
[5]   Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab - Evaluation of a new scoring system [J].
Braun, J ;
Baraliakos, X ;
Golder, W ;
Brandt, J ;
Rudwaleit, M ;
Listing, J ;
Bolow, M ;
Sieper, J ;
van der Heijde, D .
ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :1126-1136
[6]  
Braun J, 1998, ARTHRITIS RHEUM-US, V41, P58, DOI 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.3.CO
[7]  
2-7
[8]   Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial [J].
Davis, JC ;
van der Heijde, D ;
Braun, J ;
Dougados, M ;
Cush, J ;
Clegg, DO ;
Kivitz, A ;
Fleischmann, R ;
Inman, R ;
Tsuji, W .
ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3230-3236
[9]   The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1 [J].
Dinarello, CA .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (10) :732-734
[10]   SULFASALAZINE IN THE TREATMENT OF SPONDYLARTHROPATHY - A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
DOUGADOS, M ;
VANDERLINDEN, S ;
LEIRISALOREPO, M ;
HUITFELDT, B ;
JUHLIN, R ;
VEYS, E ;
ZEIDLER, H ;
KVIEN, TK ;
OLIVIERI, I ;
DIJKMANS, B ;
BERTOUCH, J ;
BROOKS, P ;
EDMONDS, J ;
MAJOR, G ;
AMOR, B ;
CALIN, A .
ARTHRITIS AND RHEUMATISM, 1995, 38 (05) :618-627